Form 4: Helius Medical Technologies Director, Blane Walter, Granted Stock Options

Director Blane Walter received stock options for 31,000 shares of Helius Medical Technologies, Inc. (HSDT) on July 2, 2024, vesting quarterly starting September 30, 2024.

Summary

• Blane Walter, a director of Helius Medical Technologies, Inc. (HSDT), was granted stock options on July 2, 2024.
• The stock options are for 31,000 shares of Class A Common Stock.
• The exercise price of the options is $0.965 per share.
• The options vest in four equal quarterly installments, beginning on September 30, 2024, contingent upon continued service.
• The options expire on July 1, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as the granting of stock options is a standard practice that aligns management interests with shareholders.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing performance and value creation.

Future Outlook

The vesting of the stock options is contingent upon the director's continued service with the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain talent, aligning their interests with the company's long-term success.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.

Key Dates

Keywords

stock options, director, Helius Medical Technologies, HSDT, equity incentive plan, beneficial ownership, Form 4